Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.73 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.58 |
| ▸ | BAD | Q92934 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ADH5 | P11766 | 1/20 | 0.55 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.54 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.54 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652691 | 1.00 | NAPRT (0.73) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| SCHEMBL21652706 | 1.00 | NAPRT (0.73) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| SCHEMBL2267228 | 0.98 | NAPRT (0.70) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL742422 | 0.98 | NAPRT (0.70) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| Terephthalic Acid SCHEMBL17360384 | 0.98 | NAPRT (0.76) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| SCHEMBL28452789 | 0.88 | NAPRT (0.57) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| Benzoic Acid SCHEMBL29139198 | 0.86 | NAPRT (0.67) | NAPRTMKNK1MKNK2TSHRPOLB | |
| SCHEMBL28365092 | 0.86 | NAPRT (0.59) | NAPRTMKNK1MKNK2HDAC1HDAC6 | |
| Isonicotinic Acid SCHEMBL1414914 | 0.85 | NAPRT (1.00) | NAPRTTP53TSHRLMNAMAPT | |
| Isonicotinic Acid SCHEMBL1108 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037226-A | Bimetallic-organic framework material for trapping trifluoromethane, preparation method thereof and adsorbent based on bimetallic-organic framework material | 西安交通大学 | 2026-05-15 | — | — | CN | claimed |
| CN-114433030-B | MOF-based organic-inorganic hybrid pore composite material for oil-water separation and preparation method thereof | 苏州优特创优新材料科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117410508-A | Electrocatalyst, and macro preparation method and application thereof | 北京化工大学 | 2024-01-16 | — | — | CN | claimed |
| CN-117143160-A | Preparation and application of pyridyl Anderson type polyacid crystal and composite material thereof | 北京理工大学 | 2023-12-01 | — | — | CN | claimed |
| CN-116836401-A | Preparation method of cobalt-based metal organic framework and application of cobalt-based metal organic framework in activating monoperoxyhydrogen sulfate to degrade organic dye | 吉林师范大学 | 2023-10-03 | — | — | CN | claimed |
| CN-112920814-B | Double transition metal-based composite liquid crystal material and preparation method thereof | 苏州量点新材料科技有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-112604715-B | Ion exchange type COF @ MOF/M composite material and preparation method thereof | 苏州段造纳米科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-112604714-B | COF @ MOF/M/L composite material and preparation method thereof | 杭州阿德旺斯材料科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-113413770-B | Preparation method and application of MOFs-PSU iodine load membrane | 富海(东营)新材料科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-112604659-B | Chiral ligand exchange type COF @ MOF/L composite material and preparation method thereof | 苏州优特创优新材料科技有限公司 | 2022-07-05 | — | — | CN | claimed |
| EP-1448200-A2 | (4-PHENYL)PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-6737530-B2 | CHEMICAL INTERMEDIATE | ASTRAZENECA AB (SE) | 2004-05-18 | — | — | US | claimed |
| US-20030166942-A1 | Chemical intermediate | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | US | claimed |
| CN-1430606-A | New process | ASTRAZENECA AB (SE) | 2003-07-16 | — | — | CN | claimed |
| WO-2003043987-A2 | (4-PHENYL) PIPERIDIN-3-YL-PHENYLCARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-1294692-A1 | NEW PROCESS | AstraZeneca AB (SE) | 2003-03-26 | — | — | EP | claimed |
| US-6392051-B2 | OXIDIZING A 4-PHENYL-N-ACYLDIHYDROPYRIDINE | CLARIANT GMBH (DE) | 2002-05-21 | — | — | US | claimed |
| WO-2001090073-A1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2001-11-29 | — | — | WO | claimed |
| US-20010021778-A1 | Process for preparing 4-(4'-carboxyphenyl)pyridine | CLARIANT GMBH | 2001-09-13 | — | — | US | claimed |
| EP-1125926-A1 | Process for the preparation of 4-(4'-carboxyphenyl)pyridine | Clariant GmbH (DE) | 2001-08-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021778-A1 | Process for preparing 4-(4'-carboxyphenyl)pyridine | NOX4, CBR1, CBR3 | NAPRT 1945/4885MKNK1 4605/4885MKNK2 4483/4885 |
| US-20030166942-A1 | Chemical intermediate | CYP4B1, UGT2B7, PAH | NAPRT 103/4885MKNK1 2643/4885MKNK2 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.